glp 1 pancreas Risk of pancreatic cancer associated with GLP-1 receptor agonist therapy Schematic presentation of the function

While there are limitations, the promise of improved diabetes management, cardiovascular benefits, and new formulations places GLP-1 agonists at the forefront of diabetes care

Ipamorelin was characterised by Raun and colleagues ( European Journal of Endocrinology , 1998) as the first selective growth-hormone secretagogue, acting on the GHS-R1a receptor cloned by Howard and colleagues ( Science , 1996)

Nat Commun (2016) 7:13329

Gao Y, Kong F, Song X, Shang J, Yao L, Xia J, Peng Y, Liu W, Gong H, Mu M, Cui H, Han T, Chen W, Wu X, Yang Y, Yan X, Jin Z, Wang P, Zhu Q, Chen L, Zhao C, Zhang D, Jin W, Wang D, Wen X, Liu C, Jia J, Mao Q, Ding Y, Jin X, Zhang Z, Mao Q, Li G, Niu J

Thereafter, the dose of Trulicity was increased every 4 weeks until the randomized dose was reached